Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis
Published: 4 January 2024| Version 1 | DOI: 10.17632/dz9vmtdwws.1
Contributors:
, , , , , , , , , Description
Supplementary Data
Files
Institutions
Pfizer Ltd
Categories
Dermatology, Dermatitis
Funding
Pfizer (United States)